TABLE 3:

Patient Demographics, Primary Cancer Diagnosis, and Number of Individual Metastatic Foci by Reviewer

Patient	Age (y)	Sex	Diagnosis	No. of Metastatic Foci on Gadolinium-Enhanced MRI		No. of Metastatic Foci on Ferumoxytol-Enhanced MRI		No. of New T2 Hypointense Lesions
				Reviewer 1 (n = 72)	Reviewer 2 (n = 78)	Reviewer 1 (n = 77)	Reviewer 2 (n = 83)	Reviewer 1 (n = 54)	Reviewer 2 (n = 57)
1	70	Male	Melanoma	1	1	1	1	1	1
2	34	Male	Melanoma	1	1	1	1	1	1
3	56	Male	Lung cancer	1	1	1	1	1	1
4	48	Female	Breast cancer	12a	14a	11a	14a	6	6
5	39	Female	Breast cancer	8a	8a	7a	8a	3	4
6	54	Female	Uterine cancer	2	2	2	2	2	2
7	53	Male	Lung cancer	2	2	2	2	2	2
8	67	Male	Renal cell carcinoma	1	1	1	1	1	1
9	79	Male	Colon cancer	1	1	1	1	1	1
10	52	Female	Lung cancer	1	1	1	1	1	1
11	60	Male	Lung cancer	2	2	2	2	2	2
12	67	Female	Ovarian cancer	2a	3a	2a	3a	0	0
13	51	Female	Breast cancer	1	1	1	1	0	0
14	52	Female	Ovarian cancer	1	1	1	1	1	1
15	53	Male	Carcinoid tumor	3a	4a	3a	4a	3	3
16	50	Female	Melanoma	13	13	13	13	11	11
17	34	Female	Lung cancer	18a	20a	25a	25a	16	18
18	68	Female	Lung cancer	1	1	1	1	1	1
19	62	Male	Lung cancer	1	1	1	1	1	1

^aDiscrepancies were found between gadolinium-enhanced and ferumoxytol-enhanced MRI.